학술논문
Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine
Document Type
Academic Journal
Author
Source
Open Forum Infectious Diseases. February, 2024, Vol. 11 Issue 2
Subject
Language
English
ISSN
2328-8957
Abstract
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant. Keywords. antibody; SARS-CoV-2; vaccine; virus.
Effective coronavirus disease 2019 (COVID-19) vaccines that elicit durable and robust neutralizing antibody responses against emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are of critical importance. In the [...]
Effective coronavirus disease 2019 (COVID-19) vaccines that elicit durable and robust neutralizing antibody responses against emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are of critical importance. In the [...]